BidaskClub Downgrades Kura Oncology (KURA) to Hold

Share on StockTwits

BidaskClub cut shares of Kura Oncology (NASDAQ:KURA) from a buy rating to a hold rating in a report published on Thursday morning.

KURA has been the topic of a number of other reports. HC Wainwright set a $31.00 price objective on Kura Oncology and gave the stock a buy rating in a research note on Tuesday, August 7th. Oppenheimer lifted their price objective on Kura Oncology from $27.00 to $35.00 and gave the stock an outperform rating in a research note on Monday, July 9th. ValuEngine raised Kura Oncology from a buy rating to a strong-buy rating in a research note on Monday, July 2nd. Finally, Cann reaffirmed a buy rating and issued a $27.00 price objective on shares of Kura Oncology in a research note on Tuesday, April 17th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of $27.00.

Shares of Kura Oncology traded down $0.10, hitting $19.10, during mid-day trading on Thursday, according to Marketbeat Ratings. 112,699 shares of the company’s stock were exchanged, compared to its average volume of 208,353. Kura Oncology has a 52 week low of $5.90 and a 52 week high of $24.02. The company has a quick ratio of 12.37, a current ratio of 10.22 and a debt-to-equity ratio of 0.04.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Thursday, August 9th. The company reported ($0.45) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.45). sell-side analysts predict that Kura Oncology will post -1.71 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of KURA. Wells Fargo & Company MN lifted its stake in Kura Oncology by 454.8% in the fourth quarter. Wells Fargo & Company MN now owns 35,105 shares of the company’s stock valued at $537,000 after buying an additional 28,777 shares during the period. Bank of New York Mellon Corp grew its holdings in Kura Oncology by 12.9% during the fourth quarter. Bank of New York Mellon Corp now owns 66,936 shares of the company’s stock worth $1,024,000 after buying an additional 7,655 shares in the last quarter. BlackRock Inc. grew its holdings in Kura Oncology by 49.1% during the fourth quarter. BlackRock Inc. now owns 1,524,817 shares of the company’s stock worth $23,331,000 after buying an additional 502,296 shares in the last quarter. Geode Capital Management LLC grew its holdings in Kura Oncology by 2.0% during the fourth quarter. Geode Capital Management LLC now owns 166,914 shares of the company’s stock worth $2,553,000 after buying an additional 3,255 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in Kura Oncology by 48.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 29,222 shares of the company’s stock worth $447,000 after buying an additional 9,590 shares in the last quarter. 71.60% of the stock is currently owned by institutional investors.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Read More: How to Use the New Google Finance Tool

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply